Teva Oral Copaxone Could Be Studied At Higher Dose After Interim Analysis
Executive Summary
Teva is considering conducting a Phase III trial evaluating a higher dose of oral Copaxone (glatiramer acetate) after an interim analysis of Teva's Phase III study of the oral formulation suggested that the trial will not meet its endpoints.